Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Consolidation Therapy with Subcutaneous Alemtuzumab After Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65–70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): Final Results of a Phase II Study From the FCGCLL/WM,

Alain Delmer, MD, Olivier Tournilhac, MD, PhD, Stéphane Leprêtre, MD, Bruno Cazin, MD, Pierre Feugier, MD, PhD, Brigitte Dreyfus, MD, Beatrice Mahe, Michel Leporrier, MD, Anne-Sophie Michallet, MD, Arnaud Jaccard, Marine Divine, MD, Vincent Levy, MD, Florence Cymbalista, Pr, Remi Letestu, MD

Blood (2011) 118 (21): 3900.

https://doi.org/10.1182/blood.V118.21.3900.3900

Published: 2011

Journal Articles

Ancestim (r-metHuSCF) Plus Filgrastim for the Mobilization and Collection of Peripheral Blood Progenitor Cells for Autologous Transplant after Failure of Prior Mobilization: The French Experience of Compassionate Use.

Valerie Lapierre, MD, PhD, Christian Chabannon, MD, Caroline Makowski, MD, Cecile Dumesnil, MD, Dominique Valteau-Couanet, MD, PhD, Anne Vekhoff, MD, Denis Caillot, MD, Nabih Azar, MD, Marine Divine, MD, Karin Blakolmer, MD, Christian Cailliot, MD, Philippe Moreau, MD, PhD, Jean-Francois Rossi, MD, PhD

Blood (2007) 110 (11): 3281.

https://doi.org/10.1182/blood.V110.11.3281.3281

Published: 2007

Journal Articles

Consolidation Therapy with Subcutaneous Alemtuzumab Following Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65-70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): A Phase II Trial of the FCGCLL/MW.

Alain Delmer, MD, Stéphane Leprêtre, MD, Bruno Cazin, MD, Pierre Feugier, MD, PhD, Olivier Tournilhac, MD, PhD, Michel Leporrier, MD, Brigitte Dreyfus, MD, Béatrice Mahé, MD, Catherine Thieblemont, MD, PhD, Marine Divine, MD, Vincent Lévy, MD, PhD, Véronique Leblond, MD, Florence Cymbalista, MD, PhD, Rémy Letestu, MD, PhD

Blood (2006) 108 (11): 2831.

https://doi.org/10.1182/blood.V108.11.2831.2831

Published: 2006

Journal Articles

Pharmacogenetic Study in Hodgkin’s Lymphomas, Impact of UGT1A1 on Prognosis.

Vincent Ribrag, MD, Serge Koscielny, phD, Olivier Casasnovas, MD, Cecile Cazeneuve, MD, phD, Pauline Brice, MD, Franck Morschhauser, MD, Jean Gabarre, MD, Marine Divine, MD, Laurent Voillat, MD, Apasia Stamatoullas, MD, Gilbert Lenoir, phD, Gilles Andre Salles, MD, phD

Blood (2006) 108 (11): 2266.

https://doi.org/10.1182/blood.V108.11.2266.2266

Published: 2006

Journal Articles

Impaired Mobilization of Peripheral Blood Stem Cell (PBSC) after Fludarabine Treatment: Comparison of Results Using 3 Different Procedures.

Philippe Genet, MD, Philippe Travade, MD, Bruno Cazin, MD, Stephane Lepretre, MD, Marine Divine, MD, Claude Martin, MD, Veronique Leblond, MD, Eric Van Den Neste, MD, Frederic Maloisel, MD, Mauricette Michallet, MD, Houchingue Eghbali, MD, Christian Berthou, MD, Alain Delmer, MD, Bernard Grosbois, MD, Pierre Feugier, MD, Michel Leporrier, MD, Laurent Sutton, MD, Olivier Tournilhac, MD

Blood (2005) 106 (11): 1978.

https://doi.org/10.1182/blood.V106.11.1978.1978

Published: 2005

Journal Articles

Single or Tandem Autologous Stem-Cell Transplantation Given According to Prognostic Factors at Relapse for Hodgkin Lymphoma.

Pauline Brice, MD, Franck Morschhauser, MD, Marine Divine, MD, Christophe Ferme, MD, Gilles Salles, MD, PD

Blood (2005) 106 (11): 2069.

https://doi.org/10.1182/blood.V106.11.2069.2069

Published: 2005

Journal Articles

Blood Flow Cytometry Allows Us To Dispense with Bone Marrow Biopsy in the Evaluation of Treatment Response in CLL.

Karim Maloum, MDPhD, Frederic Charlotte, MD, Marine Divine, MD, Bruno Cazin, MD, Stephane Lepretre, MD, Alain Delmer, MD, Sylvie Sonneville, Helene Merle-Beral, MDPhD

Blood (2004) 104 (11): 4769.

https://doi.org/10.1182/blood.V104.11.4769.4769

Published: 2004

NARROW

Consolidation Therapy with Subcutaneous Alemtuzumab After Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65–70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): Final Results of a Phase II Study From the FCGCLL/WM,

Ancestim (r-metHuSCF) Plus Filgrastim for the Mobilization and Collection of Peripheral Blood Progenitor Cells for Autologous Transplant after Failure of Prior Mobilization: The French Experience of Compassionate Use.

Consolidation Therapy with Subcutaneous Alemtuzumab Following Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65-70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): A Phase II Trial of the FCGCLL/MW.

Pharmacogenetic Study in Hodgkin’s Lymphomas, Impact of UGT1A1 on Prognosis.

Impaired Mobilization of Peripheral Blood Stem Cell (PBSC) after Fludarabine Treatment: Comparison of Results Using 3 Different Procedures.

Single or Tandem Autologous Stem-Cell Transplantation Given According to Prognostic Factors at Relapse for Hodgkin Lymphoma.

Blood Flow Cytometry Allows Us To Dispense with Bone Marrow Biopsy in the Evaluation of Treatment Response in CLL.

Email alerts

ASH Publications

American Society of Hematology

Consolidation Therapy with Subcutaneous Alemtuzumab After Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65–70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): Final Results of a Phase II Study From the FCGCLL/WM,

Ancestim (r-metHuSCF) Plus Filgrastim for the Mobilization and Collection of Peripheral Blood Progenitor Cells for Autologous Transplant after Failure of Prior Mobilization: The French Experience of Compassionate Use.

Consolidation Therapy with Subcutaneous Alemtuzumab Following Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65-70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): A Phase II Trial of the FCGCLL/MW.

Pharmacogenetic Study in Hodgkin’s Lymphomas, Impact of UGT1A1 on Prognosis.

Impaired Mobilization of Peripheral Blood Stem Cell (PBSC) after Fludarabine Treatment: Comparison of Results Using 3 Different Procedures.

Single or Tandem Autologous Stem-Cell Transplantation Given According to Prognostic Factors at Relapse for Hodgkin Lymphoma.

Blood Flow Cytometry Allows Us To Dispense with Bone Marrow Biopsy in the Evaluation of Treatment Response in CLL.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only